These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 23651018)
21. A perspective on progress in pharmacogenomics. Kerwin RW Am J Pharmacogenomics; 2003; 3(6):371-3. PubMed ID: 14672517 [No Abstract] [Full Text] [Related]
22. Concept of pharmacogenomics and future considerations. Kaur H; Grover S; Kukreti R CNS Neurosci Ther; 2013 Oct; 19(10):842-4. PubMed ID: 23919514 [No Abstract] [Full Text] [Related]
23. Drugs, diabetes and pharmacogenomics: the road to personalized therapy. Watanabe RM Pharmacogenomics; 2011 May; 12(5):699-701. PubMed ID: 21619432 [No Abstract] [Full Text] [Related]
24. Measuring the value of pharmacogenomics. Phillips KA; Van Bebber SL Nat Rev Drug Discov; 2005 Jun; 4(6):500-9. PubMed ID: 15915153 [TBL] [Abstract][Full Text] [Related]
25. DNA, drugs and chariots: on a decade of pharmacogenomics at the US FDA. Lesko LJ; Zineh I Pharmacogenomics; 2010 Apr; 11(4):507-12. PubMed ID: 20350131 [TBL] [Abstract][Full Text] [Related]
26. Statistical considerations in evaluating pharmacogenomics-based clinical effect for confirmatory trials. Wang SJ; O'Neill RT; Hung HJ Clin Trials; 2010 Oct; 7(5):525-36. PubMed ID: 20595242 [TBL] [Abstract][Full Text] [Related]
27. What is next in pharmacogenomics? Translating it to clinical practice. Valdes R; Linder MW; Jortani SA Pharmacogenomics; 2003 Jul; 4(4):499-505. PubMed ID: 12831326 [TBL] [Abstract][Full Text] [Related]
28. Count on it. Gewin V Nature; 2007 Feb; 445(7130):946-7. PubMed ID: 17361478 [No Abstract] [Full Text] [Related]
29. Drug-induced hypersensitivity reactions and pharmacogenomics: past, present and future. Alfirevic A; Pirmohamed M Pharmacogenomics; 2010 Apr; 11(4):497-9. PubMed ID: 20350129 [TBL] [Abstract][Full Text] [Related]
30. Evolution of pharmacogenomics. Somogy A Proc West Pharmacol Soc; 2008; 51():1-4. PubMed ID: 19544663 [TBL] [Abstract][Full Text] [Related]
31. Shifting emphasis from pharmacogenomics to theragnostics. Ozdemir V; Williams-Jones B; Glatt SJ; Tsuang MT; Lohr JB; Reist C Nat Biotechnol; 2006 Aug; 24(8):942-6. PubMed ID: 16900136 [TBL] [Abstract][Full Text] [Related]
33. Clinical pharmacogenomics: opportunities and challenges at point of care. Scott SA Clin Pharmacol Ther; 2013 Jan; 93(1):33-5. PubMed ID: 23212102 [No Abstract] [Full Text] [Related]
34. Pharmacogenomics of β-blockers and statins: possible implications for perioperative cardiac complications. Kertai MD; Fontes M; Podgoreanu MV J Cardiothorac Vasc Anesth; 2012 Dec; 26(6):1101-14. PubMed ID: 22889606 [No Abstract] [Full Text] [Related]
35. Hypertension pharmacogenomics: current status and future directions. Johnson JA; Turner ST Curr Opin Mol Ther; 2005 Jun; 7(3):218-25. PubMed ID: 15977418 [TBL] [Abstract][Full Text] [Related]
36. Translating pharmacogenomics discoveries into clinical practice: the role of curated databases. Nadkarni PM; Wiepert M Pharmacogenomics; 2005 Jul; 6(5):451-4. PubMed ID: 16013993 [TBL] [Abstract][Full Text] [Related]
37. Emergence and evolution of pharmacogenetics and pharmacogenomics in clinical pharmacy over the past 40 years. Streetman DS Ann Pharmacother; 2007 Dec; 41(12):2038-41. PubMed ID: 17956958 [No Abstract] [Full Text] [Related]
38. Advances in pharmacogenomics and individualized drug therapy: exciting challenges that lie ahead. Nebert DW; Vesell ES Eur J Pharmacol; 2004 Oct; 500(1-3):267-80. PubMed ID: 15464039 [TBL] [Abstract][Full Text] [Related]
39. The pharmacogenomics of depression. Licinio J; Wong ML Pharmacogenomics J; 2001; 1(3):175-7. PubMed ID: 11908753 [No Abstract] [Full Text] [Related]